Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

Edwards Discontinues Centera TAVR Program As Sapien Sales Continue To Climb

Jul 24 2019

• By Reed Miller

Rising-graph-line — • Source: shutterstock.com

Related Content

ACC Results Recap Part I: Low-Risk TAVR Trials Bring Good News For Edwards And Medtronic; Apple Watch Detects AFib In Apple Heart Study

Mar 19 2019

Manufacturers Support CMS’ New TAVR National Coverage Decision

Jun 24 2019

Edwards’ Pascal Improves Mitral Regurgitation In Early Trial Results

Apr 12 2019

Edwards Lifesciences Buys CAS For $100M

Feb 12 2019

Edwards’ Resilia Surgical Valve Proves Durability in COMMENCE Study

May 07 2019

CRT 2018: Late-Breakers Feature Sapien MR, Selution DCB, Low-Risk TAVR, and Radial Access PCI

Mar 12 2018

Latest Sapien Valve Gets EU Go-Ahead, But Germany Will Have To Wait

Nov 16 2018

Starts & Stops: 2017 Finishes With Progress For Edwards, Stalled Trials For Boston Scientific

Jan 16 2018

Related Companies

Edwards Lifesciences Corp.

Abbott

Additional Topics

Sales & Earnings Companies Commercial Approvals Clinical Trials Cardiology Cardiovascular Medical Device

More from Business

More from Medtech Insight

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window